7月31日，艾伯维公司盘中下跌3.04%，报251.87美元/股，成交额3.18亿美元。
消息面上，公司当日发布第二季度财报，调整后每股收益3.65美元，超市场预期的3.60美元；营收169.9亿美元，超预期的167.8亿美元，同比增长显著，其中核心产品Skyrizi和Rinvoq销售均小幅超预期。然而，公司将全年调整后每股收益指引下调至13.87至14.07美元，低于此前的13.91至14.11美元，亦低于市场预期的14.06美元。指引下调主要源于收购Apogee Therapeutics带来的每股约0.14美元摊薄影响，以及第二季度计入的2.91亿美元IPR&D费用对每股收益造成的0.17美元拖累。业绩兑现后，市场对全年盈利前景的担忧触发获利回吐。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.